By Tim Wright, Editor, Contract Pharma03.01.18
Oral solids continue to be the most common dosage form in the pharmaceutical market. They are cost-effective, easy to manufacture and patient-friendly. Advances in drug delivery technology, such as targeted drug delivery and sustained release dosage forms, are enabling oral solids to achieve even greater levels of bioavailability while reducing the frequency of drug administration.
Other benefits exist, according to Justin Schroeder, executive director, marketing, business development and design, PCI Pharma Services, in terms of “relatively uncomplicated packaging needs and storage and distribution requirements due to chemical and physical stability.”
Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from $493.2 billion in 2017 to $926.3 billion by 2027, representing a compound annual growth rate (CAGR) of 6.5%. According to IMS Health, nine of the top 10 drugs based on monthly prescription volume are oral solid doses and the top selling drug by sales figures is also an oral solid dose.
Other benefits exist, according to Justin Schroeder, executive director, marketing, business development and design, PCI Pharma Services, in terms of “relatively uncomplicated packaging needs and storage and distribution requirements due to chemical and physical stability.”
Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from $493.2 billion in 2017 to $926.3 billion by 2027, representing a compound annual growth rate (CAGR) of 6.5%. According to IMS Health, nine of the top 10 drugs based on monthly prescription volume are oral solid doses and the top selling drug by sales figures is also an oral solid dose.
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION